Countries that embrace legal regulation find themselves in breach of international law. In this video, we explain a strategy to resolve those treaty tensions and to enable progressive and sustainable change at the global level.
Martin Jelsma, Neil Boister, David Bewley-Taylor, Malgosia Fitzmaurice, John Walsh
15 March 2018
Legal tensions are growing within the international drug control regime as increasing numbers of member states move towards or seriously consider legal regulation of the cannabis market for non-medical purposes. Amongst reform options not requiring consensus, inter se modification appears to be the most ‘elegant’ approach and one that provides a useful safety valve for collective action to adjust a treaty regime arguably frozen in time.
The admission by UN's lead agency for drugs, the UNODC, that “the drug market is thriving” in its 2017 World Drug Report is an important one given that it is months away from 2019 – the target date by which governments committed to “significantly reduce or eliminate” the global drug market. At the recent annual gathering of the Commission on Narcotic Drugs (CND) in Vienna, this abysmal failure to claim any progress towards these ‘drug-free’ targets was the backdrop to the latest round of tense negotiations on global drug control.
Today, on the United Nations’ International Day Against Drug Abuse and Illicit Trafficking (26th June), governments around the world are commemorating their decades-long support of the global war on drugs.
After decades of relative tolerance towards Cannabis in Spain, the Constitutional Court decides that cannabis clubs are criminal. Years of government criminalizing strategy pay off. The national parliamentary debate can no longer be postponed.
As a growing number of countries move towards legal regulation for non-medical cannabis, governments are pushing the boundaries of the three UN drug control treaties. At the 61st session of the Commission on Narcotic Drugs (CND), TNI will co-organise a side event to explore the issue, addressing the various challenges and opportunities involved.
The recent publication of two single pieces of legislation - the amended 1993 Narcotic Drugs and Psychotropic Substances Law and the first National Drug Control Policy - is likely to form the basis of Myanmar’s drug policy for several years to come. What does it mean for the country’s transition towards an evidence-based approach to drug control, and how can the gaps between the two documents be addressed?